The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-18 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Isoenzyme patterns differ in tissues. Skeletal muscle expresses CK-MM (98%) and low levels of CK-MB (1%). The myocardium (heart muscle), in contrast, expresses CK-MM at 70% and CK-MB at 25–30%. CK-BB is predominantly expressed in brain and smooth muscle, including vascular and uterine tissue.
No party has won a single majority in the Riksdag since 1968. Political parties with similar agendas consequently cooperate on several issues, forming coalition governments or other formalized alliances. Two major blocs existed in parliament until 2019, the socialist/green Red-Greens and the conservative/liberal Alliance. The latter—consisting of the Moderate Party, Liberals, Centre Party, and Christian Democrats—governed Sweden from 2006 through most of 2014 (after 2010 through a minority government). The Red-Greens combination disbanded on 26 October 2010 but continued to be considered the main opposition until the 2014 election, following which the Social Democrats and the Green Party formed a government with support from the Left Party. In 2019, after the 2018 election in which neither bloc won a majority of seats, the Social Democrats and Green Party formed a government with support from the Liberals and Centre Party, breaking the center-right Alliance. In March 2019, the Christian Democrats and Moderate Party signaled a willingness to talk with the Sweden Democrats.
The term "herbal medicine" is somewhat misleading in that, while plant elements are by far the most commonly used substances in TCM, other, non-botanic substances are used as well: animal, human, fungi, and mineral products are also used. Thus, the term "medicinal" (instead of herb) may be used. A 2019 review of traditional herbal treatments found they are widely used but lacking in scientific evidence, and urged a more rigorous approach by which genuinely useful medicinals might be identified.
=== Legal categorization and legal issues in a near future === Currently, siRNAs are chemically synthesized and are therefore legally categorized in the EU and the US as simple medicinal products. But as bioengineered siRNA (BERAs) are in development, these would be classified as biological medicinal products, at least in the EU. The development of the BERAs technology raises the question of the categorization of drugs having the same mechanism of action but being produced chemically or biologically. This lack of consistency should be addressed.
=== Genetically modified food === In 2015, Ayyadurai published a paper that applied systems biology, which uses mathematical modeling, to predict the chemical composition of genetically modified (GM) soybeans, and whether or not they were substantially equivalent to unmodified soybeans. The paper claimed that GM soybeans have lower levels of the antioxidant glutathione and higher levels of carcinogenic formaldehyde, making the modified soybean substantially different, contrary to previous safety assessments. Shortly after publication, Ayyadurai embarked on a speaking tour of the U.S. At the National Press Club, he said that genetic modification had "fundamentally modified the metabolic system of the soy", disrupting the "beautiful way of detoxifying [formaldehyde]" present in non-GM soy. The European Food Safety Agency evaluated the paper and determined that "the author's conclusions are not supported" due to the lack of information on the input into the model, the fact that the model was not validated and because no measurements of soybeans were made to establish whether GM soy actually contained elevated levels of formaldehyde. Plant scientist Kevin Folta noted that there was "no evidence ever published ... that shows a difference in formaldehyde between GM and non-GM varieties". Ayyadurai later cited the study as evidence of a lack of safety standards for GM foods and bet Monsanto a $10 million building if they could prove that they were safe.
Sources: en.wikipedia.org
=== Infertility === HHV-6A DNA was found in the endometrium of almost half of a group of infertile women, but in none of the fertile control group. Natural killer cells specific for HHV-6A, and high uterine levels of certain cytokines, were also found in the endometrium of the infertile women positive for HHV-6A. The authors suggest that HHV-6A may prove to be an important factor in female infertility.
deoxyribose Also 2-deoxyribose. A monosaccharide pentose sugar derived from ribose by the replacement of the hydroxyl group attached to the C2 carbon with a single hydrogen atom. D-deoxyribose, in its cyclic ring form, is one of three main functional groups of deoxyribonucleotides and hence of deoxyribonucleic acid (DNA) molecules.
== LCRs and the protopeptides of the early genetic code == The amino acids with the highest frequency in LCRs are glycine and alanine, with their respective codons GGC and GCC being the most frequent, as well as complementary. In eukaryotes and more specifically in chordates (such as human, mouse, chicken, zebrafish and sea squirt), alanine- and glycine-rich LCRs are over-represented in recently formed LCRs and probably are better tolerated by the cell. Intriguingly, it has also been suggested that they represent the very first two amino acids and codons of the early genetic code. Thus, these two codons and their respective amino acids must have been constituents of the earliest oligopeptides, with a length of 10–55 amino acids and very low complexity. Based on several different criteria and sources of data, Higgs and Pudritz suggest G, A, D, E, V, S, P, I, L, T as the early amino acids of the genetic code. Trifonov's work largely agrees with this categorization and proposes that the early amino acids in chronological order are G, A, D, V, S, P, E, L, T, R. An evolutionary analysis observed that many of the amino acids of the suggested very early genetic code (with the exception of the hydrophobic ones) are significantly enriched in bacterial LCRs. Most of the later additions to the genetic code are significantly under-represented in bacterial LCRs. They thus hypothesize and propose that, in a cell-free environment, the early genetic code may have also produced low complexity oligo-peptides from valine and leucine.
== Introduction == Although the term fluid generally includes both the liquid and gas phases, its definition varies among branches of science. Definitions of solid vary as well, and depending on field, some substances can have both fluid and solid properties. Non-Newtonian fluids like Silly Putty appear to behave similar to a solid when a sudden force is applied. Substances with a very high viscosity such as pitch appear to behave like a solid (see pitch drop experiment) as well. In particle physics, the concept is extended to include fluidic matters other than liquids or gases. A fluid in medicine or biology refers to any liquid constituent of the body (body fluid), whereas "liquid" is not used in this sense. Sometimes liquids given for fluid replacement, either by drinking or by injection, are also called fluids (e.g. "drink plenty of fluids"). In hydraulics, fluid is a term which refers to liquids with certain properties, and is broader than (hydraulic) oils.
Sources: en.wikipedia.org
Patients with diabetes are oriented to avoid exceeding the recommended postprandial threshold of 160 mg/dL (8.89 mmol/L) for optimal glycemic control. Values of blood glucose higher than 160 mg/dL are classified as 'very high' hyperglycemia, a condition in which an excessive amount of glucose (glucotoxicity) circulates in the blood plasma. These values are higher than the renal threshold of 10 mmol/L (180 mg/dL) up to which glucose reabsorption is preserved at physiological rates and insulin therapy is not necessary. Blood glucose values higher than the cutoff level of 11.1 mmol/L (200 mg/dL) are used to diagnose T2DM and strongly associated with metabolic disturbances, although symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/L (~250–300 mg/dL). A subject with a consistent fasting blood glucose range between 5.6–7 mmol/L (~100–126 mg/dL) (American Diabetes Association guidelines) is considered slightly hyperglycemic, and above 7 mmol/L (126 mg/dL) is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dL) can produce noticeable organ damage over time.
ICT appears to be vanishing as a result of greater genetic diversity within the affected populations in conjunction with educational programs to ensure that tinned cooking utensils are used instead of copper pots and pans being directly exposed to cooked foods. The preponderance of cases of early childhood cirrhosis identified in Germany over a period of 10 years were not associated with either external sources of copper or with elevated hepatic metal concentrations Only occasional spontaneous cases of ICT arise today.
Second, critics say its policies promoted heavy input use and dependence on agrochemicals, which led to adverse environmental effects like soil degradation and chemical runoff. Digital agriculture technologies have the potential to address negative side effects of the Green Revolution. In some ways, the Digital Agriculture Revolution follows patterns of previous agricultural revolutions. Scholars forecast a further shift away from labor, a slight shift away from capital, and intensified use of human capital, continuing the trend the British Agricultural Revolution started. Also, many predict that social backlash, possibly around the use of artificial intelligence or robots, will arise with the fourth revolution. In other ways, the Digital Agriculture Revolution is distinct from its predecessors. First, digital technologies will affect all parts of the agricultural value chain, including off-farm segments. This differs from the first three agricultural revolutions, which primarily impacted production techniques and on-farm technologies. Second, a farmer's role will require more data analytics skills and less physical interaction with livestock/fields. Third, although farming has always relied on empirical evidence, the volume of data and the methods of analysis will undergo drastic changes in the digital revolution. For example, smart farm systems continuously monitor animal behavior, giving insight into their activities at all times.
== Human proteins containing laminin domains == Laminin domain I: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin domain II: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin B (domain IV): all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5), gamma chains (LAMC1, LAMC2, LAMC3), and perlecan (HSPG2) Laminin EGF-like (domains III and V): all laminin chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, LAMB1, LAMB2, LAMB3, LAMB4, LAMC1, LAMC2, LAMC3), attractins (ATRN, ATRNL1), cadherin EGF LAG seven-pass G-type receptors (CELSR1, CELSR2, CELSR3), cysteine-rich with EGF-like domain proteins (CRELD1, CRELD2), multiple EGF-like domain proteins (MEGF6, MEGF8, MEGF9, MEGF10, PEAR1), most netrins (NTN1, NTN3, NTN4, NTNG1, NTNG2), mucins 3A and 3B (MUC3A, MUC3B), class F scavenger receptors (SCARF1, SCARF2), stabilins (STAB1, STAB2), agrin (AGRIN), angiopoietin-1 receptor (TEK), perlecan (HSPG2), tenascin N (TNN), and usherin (USH2A).
pnictogen Any of the chemical elements belonging to Group (V) of the periodic table: nitrogen (N), phosphorus (P), arsenic (As), antimony (Sb), bismuth (Bi), and moscovium (Ms). These elements are united by their common pentavalency; i.e. in their non-ionized states, atoms of these elements all have exactly five valence electrons in their outermost electron shell, three short of a complete octet.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.